ReviewRSC advances2025
Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- From Laboratory to Patient Access: A Scoping Review of the Multi-Dimensional Challenges in Drug Repurposing.Pharmacy (Basel, Switzerland) · 2026Review
- Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance.International journal of molecular sciences · 2026Review
- Design, Synthesis, In Vitro, and In Silico Assessment of Fluoroquinolone-Sulfonamide Hybrids as Promising Antibacterial Agents.Chemistry & biodiversity · 2026Article
- Beyond new pills: integrative strategies to overcome multidrug-resistant bacteria.Archives of microbiology · 2026Review
- From Polyphenols to β-Lactamases: Multitarget Strategies to Defeat Severe Resistance.International journal of molecular sciences · 2026Review
- Novel recombinant VH43 antibody fragment potentiates the antibacterial activity of cephalosporins against Enterococcus faecium.Archives of microbiology · 2026Article
- Reversal of tetracycline resistance by clove and peony extracts in a multi-drug resistant Escherichia coli.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Evaluation of the effects of hybrids of metronidazole and eugenol analogues as inhibitors of the Staphylococcus aureus NorA efflux pump: an in vitro and in silico analysis.Folia microbiologica · 2026Article
- Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- A Critical Review of Quorum-Sensing Inhibition Strategies in Klebsiella Pneumoniae.Current microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance poses a formidable threat to human health, representing a critical challenge that demands urgent attention. Without decisive feat, we confront the alarming prospect of a world where effective antibiotics are no longer available. Bacteria employ various mechanisms to elude antibiotics, including modifying antibiotic targets, utilizing efflux pumps to avoid antibiotics, and inactivating antibiotics. This review focuses on small-molecule-based approaches to overcoming resistance, with emphasis on chemical adjuvants (such as β-lactamase inhibitors, efflux pump inhibitors, and membrane permeabilizers), synergistic combination therapies, repurposed non-antibiotic drugs, and structural modifications of known antibiotics like ciprofloxacin. We critically analyze structure-activity relationships (SAR), biochemical mechanisms, and clinical barriers associated with each strategy. By addressing antibiotic resistance, we aim to fortify our ability to combat bacterial infections effectively and sustain the efficacy of existing antibiotics in the face of evolving resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.